---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-124869"
form_type: "8-K"
ticker: "MRKR"
cik: "0001094038"
company_name: "Marker Therapeutics, Inc."
filed_at: "2023-12-11T23:59:59+00:00"
generated_at: "2026-06-07T14:40:58.720270+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Marker Therapeutics reports sustained complete response in Phase 1 lymphoma patient at 6 months

## Summary
- DLBCL patient who failed anti-CD19 CAR T and 3 prior therapies achieved CR at 8 weeks and remains in CR at 6 months after MT-601.
- MT-601 is a multiTAA-specific T cell therapy, non-genetically engineered, well-tolerated without severe CAR T side effects like neurotoxicity.
- Up to 60% of lymphoma patients relapse within one year after CAR T; this patient had relapsed within 90 days yet maintained response.
- Company has enrolled additional patients in APOLLO study to replicate results; City of Hope is the trial site.
- Non-clinical data shows MT-601 can eradicate lymphoma cells resistant to anti-CD19 CAR T in vitro.

## SEC filing metadata
- accession: 0001104659-23-124869
- form_type: 8-K
- ticker: MRKR
- cik: 0001094038
- company_name: Marker Therapeutics, Inc.
- filed_at: 2023-12-11T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1094038/000110465923124869/0001104659-23-124869-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1094038/000110465923124869/tm2332541d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-124869
- JSON: https://secwatch.observer/filing/0001104659-23-124869.json
- Plain text: https://secwatch.observer/filing/0001104659-23-124869.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.